Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Menopause Coverage topic
No spam. Unsubscribe anytime.
Committee adopts amendment and refers menopause coverage bill to Ways and Means
Summary
The committee adopted the dash‑1 amendment to House Bill 3,064 (coverage for perimenopause/menopause services limited to FDA‑approved drugs) and voted to refer the bill to the Joint Committee on Ways and Means by prior reference.
The committee opened a work session on House Bill 3,064, a proposal requiring certain health insurance plans to cover services for perimenopause, menopause and post‑menopause treatment. Staff described a dash‑1 amendment that limits coverage to drugs approved by the U.S. Food and Drug Administration and aligns the bill for a subreferral to the Joint Committee on Ways and Means.
Vice Chair Javidy moved to adopt the dash‑1 amendment dated 02/25/2025; the committee adopted the amendment without recorded objection. Vice Chair Javidy then moved the bill, as amended, to the floor with a due‑pass recommendation and prior referral to Ways and Means.
The committee conducted a roll call. Recorded votes were: Representative Beal — yes; Representative Harvick — yes; Representative Isidore — yes; Representative McIntyre — excused; Representative Munoz — yes; Representative Pham — yes; Vice Chair Javidy — yes; Vice Chair Nelson — yes; Chair (Rob Nose) — yes. The committee clerk announced the bill was adopted by the committee and will be referred to the Joint Committee on Ways and Means.
